Regulatory approval
Published by the Health Canada. Approved
TECENTRIQ (atezolizumab, concentrate for solution for infusion) is indicated as monotherapy, as adjuvant treatment following complete resection and no progression after platinum-based adjuvant chemotherapy for adult patients with Stage II to IIIA* NSCLC whose tumours have PD-L1 expression on >= 50% of tumour cells (TCs)
This is written in the approval document.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HC (1) | PD-L1 >= 50% | Non-Small Cell Lung Cancer | Atezolizumab |